Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a progestin presented as an intrauterine system for intrauterine use. It prevents pregnancy by locally thickening cervical mucus, inhibiting sperm motility, and suppressing endometrial growth, providing long‑acting reversible contraception for women of reproductive age.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Clients benefit from reliable logistics, competitive pricing, and dedicated technical support throughout the supply chain.

Kyleena, a levonorgestrel‑releasing intrauterine system, is used within the hormonal contraception pathway to prevent pregnancy. - Contraception: provides up to five years of highly effective pregnancy prevention. - Family planning: offers a long‑acting reversible option for women seeking reliable birth control. - Hormonal birth control: delivers continuous low‑dose levonorgestrel to suppress ovulation and thicken cervical mucus. - Menstrual regulation: can reduce heavy bleeding and improve cycle regularity in some users.

The intrauterine system may be associated with a range of adverse reactions, most of which are mild and resolve with time.

Common Side Effects: - Irregular vaginal bleeding or spotting. - Amenorrhea (absence of periods). - Pelvic or abdominal cramping.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Device expulsion or displacement. - Pelvic inflammatory infection.

Before insertion and during use, several precautions should be observed to minimise risks. - Contraindications: exclude women with active pelvic infection, unexplained vaginal bleeding, or known uterine anomalies. - Pregnancy testing: confirm non‑pregnant status prior to placement. - Medical history: assess for hormone‑sensitive cancers or liver disease. - Follow‑up: schedule a post‑insertion check to verify correct positioning. - Store at ambient temperature: keep the device in its original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Kyleena can interact with other medicines that affect hormone metabolism or increase infection risk.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin): may lower levonorgestrel efficacy. - Rifampin or other strong CYP3A4 inducers: can reduce contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Antifungal agents (ketoconazole, itraconazole): may increase systemic levonorgestrel levels. - St John’s wort: may modestly decrease hormone concentration. - Combined hormonal contraceptives: concurrent use may increase overall hormonal exposure.